JP2023519807A5 - - Google Patents
Info
- Publication number
- JP2023519807A5 JP2023519807A5 JP2022550848A JP2022550848A JP2023519807A5 JP 2023519807 A5 JP2023519807 A5 JP 2023519807A5 JP 2022550848 A JP2022550848 A JP 2022550848A JP 2022550848 A JP2022550848 A JP 2022550848A JP 2023519807 A5 JP2023519807 A5 JP 2023519807A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cancer
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981355P | 2020-02-25 | 2020-02-25 | |
| US62/981,355 | 2020-02-25 | ||
| US202063105104P | 2020-10-23 | 2020-10-23 | |
| US63/105,104 | 2020-10-23 | ||
| PCT/US2021/019667 WO2021173832A1 (en) | 2020-02-25 | 2021-02-25 | Cancer treatment methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519807A JP2023519807A (ja) | 2023-05-15 |
| JP2023519807A5 true JP2023519807A5 (https=) | 2024-02-26 |
Family
ID=75143716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550848A Pending JP2023519807A (ja) | 2020-02-25 | 2021-02-25 | 癌治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230165968A1 (https=) |
| EP (1) | EP4110403A1 (https=) |
| JP (1) | JP2023519807A (https=) |
| KR (1) | KR20220145871A (https=) |
| AU (1) | AU2021226570A1 (https=) |
| CA (1) | CA3169117A1 (https=) |
| WO (1) | WO2021173832A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2024130003A1 (en) | 2022-12-15 | 2024-06-20 | Bolt Biotherapeutics, Inc. | Cancer combination treatment method |
| CA3221817A1 (en) * | 2023-06-30 | 2025-06-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Combination therapies for the treatment of cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| WO2007038720A2 (en) * | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2017087280A1 (en) * | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| KR20180134347A (ko) * | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| CN109843327B (zh) * | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| US20180271996A1 (en) * | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| CA3100544A1 (en) * | 2018-05-17 | 2019-11-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
| US20220152215A1 (en) * | 2019-03-15 | 2022-05-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting CEA |
| US20220143012A1 (en) * | 2019-03-15 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Macromolecule-Supported TLR Agonists |
| WO2020190725A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20220226491A1 (en) * | 2019-03-15 | 2022-07-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting PD-L1 |
| WO2020190731A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
-
2021
- 2021-02-25 CA CA3169117A patent/CA3169117A1/en active Pending
- 2021-02-25 KR KR1020227032892A patent/KR20220145871A/ko active Pending
- 2021-02-25 EP EP21713788.4A patent/EP4110403A1/en not_active Withdrawn
- 2021-02-25 US US17/802,392 patent/US20230165968A1/en not_active Abandoned
- 2021-02-25 JP JP2022550848A patent/JP2023519807A/ja active Pending
- 2021-02-25 AU AU2021226570A patent/AU2021226570A1/en not_active Abandoned
- 2021-02-25 WO PCT/US2021/019667 patent/WO2021173832A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026035673A (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 | |
| JP2023519807A5 (https=) | ||
| JP2019519499A5 (https=) | ||
| JP7769032B2 (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| CN111629788A (zh) | 用拮抗性抗-pd-1抗体治疗癌症的方法 | |
| KR20200130356A (ko) | 항-조직 인자 항체-약물 접합체 및 암 치료에서의 그의 용도 | |
| US20230398229A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| JP2023025036A (ja) | がんの処置のためのアベルマブの投与レジメン | |
| JP2025148452A5 (https=) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| TW202306588A (zh) | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 | |
| JP2022502079A5 (https=) | ||
| JP2024536383A5 (https=) | ||
| WO2024183622A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| JP2024538755A5 (https=) | ||
| US20230061858A1 (en) | Treatment with site specific her2 antibody-drug conjugates | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| CN113574070B (zh) | 用于治疗骨肉瘤的组合物和使用方法 | |
| HK40109224A (zh) | 抗体-药物缀合物与免疫检查点抑制剂组合用於治疗尿路上皮癌的用途 | |
| WO2025162211A1 (zh) | 抗her2抗体药物偶联物治疗胃癌的用途 | |
| JP2025508739A5 (https=) | ||
| WO2024183623A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| EP4694894A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor | |
| WO2026061538A1 (zh) | 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合 |